Bortezomib

Product Description

Bortezomib is a high affinity proteasome inhibitor (K_i = 0.6 nM). Inhibits growth of multiple myeloma (MM) cell lines (IC₅₀ values in <50 nM range); induces apoptosis in MM cell lines and MM patient derived cells, including p53 mutant cell lines. Decreases adherence of MM cells lines to bone marrow stromal cells (BMSCs). Acts synergistically with dexamethasone (Cat. No. 1126). Also cytotoxic in MCF-7 breast cancer cell line (IC₅₀ = 50 nM).

Solubility

Preparing Stock Solutions for Bortezomib

The following data is based on the product molecular weight 384.24

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1.31 mM	1.99 mL	9.93 mL	19.87 mL
6.55 mM	0.40 mL	1.99 mL	3.97 mL
13.1 mM	0.20 mL	0.99 mL	1.99 mL
65.5 mM	0.04 mL	0.20 mL	0.40 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Hideshima The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001 PMID: 11306489
• Teicher The proteasome inhibitor PS-341 in cancer therapy. Clin.Cancer Res. 1999 PMID: 10499643